{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:19Z","timestamp":1793316259983,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":924,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1038\/s41379-020-0461-z","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T12:03:47Z","timestamp":1579781027000},"page":"1275-1286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Intense basolateral membrane staining indicates HER2 positivity in invasive micropapillary breast carcinoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Shuling","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianming","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohong","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-020-0461-z_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3747\/co.2007.131","article-title":"Updated recommendations from the Canadian National Consensus Meeting on HER2\/neu testing in breast cancer","volume":"14","author":"Hanna","year":"2007","journal-title":"Curr Oncol."},{"key":"10.1038\/s41379-020-0461-z_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.MP.0000052102.90815.82","article-title":"Current perspectives on HER2 testing: a review of national testing guidelines","volume":"16","author":"Bilous","year":"2003","journal-title":"Mod Pathol."},{"key":"10.1038\/s41379-020-0461-z_bib3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.5858\/133.5.775","volume":"133","author":"Middleton","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/s41379-020-0461-z_bib4","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2005.03.4744","article-title":"HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0461-z_bib5","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0461-z_bib6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMc0801440","article-title":"HER2 status and benefit from adjuvant trastuzumab in breast cancer","volume":"358","author":"Paik","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-020-0461-z_bib7","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0461-z_bib8","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0461-z_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/his.12147","article-title":"The clinical relevance of micropapillary carcinoma of the breast: a case-control study","volume":"63","author":"Vingiani","year":"2013","journal-title":"Histopathology."},{"key":"10.1038\/s41379-020-0461-z_bib10","unstructured":"Gabriel N, Hortobagyi JLC. AJCC Cancer Staging Manual. In: Mahul B Amin SEFG (ed). AJCC Cancer Staging Manua. 8 edn. NY: Springer International Publishing: New York, 2016."},{"key":"10.1038\/s41379-020-0461-z_bib11","unstructured":"Allison KH, Brogi E, Ellis LO, Fox Stephen B, Morris Elizabeth A, Sahin A, et al. WHO Classification of Tumors of the Breast. 5th ed. International Agency for Research on Cancer: Lyon, 2019, p 104."},{"key":"10.1038\/s41379-020-0461-z_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/bjc.1957.43","article-title":"Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years","volume":"11","author":"Bloom","year":"1957","journal-title":"Br J Cancer"},{"key":"10.1038\/s41379-020-0461-z_bib13","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0461-z_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","article-title":"HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing","volume":"457","author":"Ruschoff","year":"2010","journal-title":"Virchows Arch."},{"key":"10.1038\/s41379-020-0461-z_bib15","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol."},{"key":"10.1038\/s41379-020-0461-z_bib16","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.suronc.2008.11.001","article-title":"Herceptin and breast cancer: an overview for surgeons","volume":"19","author":"Patani","year":"2010","journal-title":"Surg Oncol."},{"key":"10.1038\/s41379-020-0461-z_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ctrv.2012.03.009","article-title":"Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials","volume":"39","author":"Brollo","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1038\/s41379-020-0461-z_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1746-1596-5-50","article-title":"Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization","volume":"5","author":"Vogel","year":"2010","journal-title":"Diagn Pathol."},{"key":"10.1038\/s41379-020-0461-z_bib19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist."},{"key":"10.1038\/s41379-020-0461-z_bib20","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.2012.44.8027","article-title":"Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006","volume":"31","author":"Rimawi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0461-z_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00432-013-1409-1","article-title":"Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer","volume":"139","author":"Tonyali","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1038\/s41379-020-0461-z_bib22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2214\/ajr.179.4.1790927","article-title":"Invasive micropapillary carcinoma of the breast: clinical, mammographic, and sonographic findings with histopathologic correlation","volume":"179","author":"Gunhan-Bilgen","year":"2002","journal-title":"AJR Am J Roentgenol"},{"key":"10.1038\/s41379-020-0461-z_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2559.2004.01757.x","article-title":"Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma","volume":"44","author":"Zekioglu","year":"2004","journal-title":"Histopathology."},{"key":"10.1038\/s41379-020-0461-z_bib24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/tbj.12128","article-title":"Invasive micropapillary carcinoma of the breast: a clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma","volume":"19","author":"Gokce","year":"2013","journal-title":"Breast J."},{"key":"10.1038\/s41379-020-0461-z_bib25","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1309\/AXYY4AJTMNW6FRMW","article-title":"Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis","volume":"126","author":"Guo","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/s41379-020-0461-z_bib26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/hupa.2001.24988","article-title":"Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity","volume":"32","author":"Walsh","year":"2001","journal-title":"Hum Pathol."},{"key":"10.1038\/s41379-020-0461-z_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1309\/YMJ3A83TB39MRUT9","article-title":"Correlation of HER-2 Status With Estrogen and Progesterone Receptors and Histologic Features in 3,655 Invasive Breast Carcinomas","volume":"123","author":"Lal","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/s41379-020-0461-z_bib28","first-page":"854","article-title":"Correlation of human epidermal growth factor receptor 2 (HER-2\/neu) receptor status with hormone receptors Oestrogen Receptor, Progesterone Receptor status and other prognostic markers in breast cancer: an experience at tertiary care hospital in Karachi","volume":"63","author":"Mujtaba","year":"2013","journal-title":"J Pak Med Assoc"},{"key":"10.1038\/s41379-020-0461-z_bib29","first-page":"553","article-title":"Comparison of ER, PR and HER-2\/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer","volume":"9","author":"Azizun-Nisa","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1038\/s41379-020-0461-z_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-004-8235-8","article-title":"Association between HER-2\/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related","volume":"91","author":"Huang","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-020-0461-z_bib31","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdi326","article-title":"Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005","volume":"16","author":"Goldhirsch","year":"2005","journal-title":"Ann Oncol."},{"key":"10.1038\/s41379-020-0461-z_bib32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1309\/XTJ7VHB49UD78X60","article-title":"Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior","volume":"121","author":"Pettinato","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/s41379-020-0461-z_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1440-1827.2004.01590.x","article-title":"Invasive micropapillary carcinoma of the breast: clinicopathological and immunohistochemical study","volume":"54","author":"De la Cruz","year":"2004","journal-title":"Pathol Int."},{"key":"10.1038\/s41379-020-0461-z_bib34","first-page":"48","article-title":"Evaluation of immunohistochemistry HER2 results interpretation in Invasive micropapillary carcinoma of the breast","volume":"44","author":"Yang","year":"2015","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"10.1038\/s41379-020-0461-z_bib35","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/modpathol.2017.65","article-title":"HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features","volume":"30","author":"Stewart","year":"2017","journal-title":"Mod Pathol."},{"key":"10.1038\/s41379-020-0461-z_bib36","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","article-title":"Evaluation of HER-2\/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens","volume":"20","author":"Press","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-0461-z_bib37","first-page":"208","article-title":"Her2 testing in gastric cancer. What is different in comparison to breast cancer?","volume":"31","author":"Ruschoff","year":"2010","journal-title":"Pathologe"},{"key":"10.1038\/s41379-020-0461-z_bib38","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology."},{"key":"10.1038\/s41379-020-0461-z_bib39","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet."},{"key":"10.1038\/s41379-020-0461-z_bib40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"Ruschoff","year":"2012","journal-title":"Mod Pathol."},{"key":"10.1038\/s41379-020-0461-z_bib41","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3346\/jkms.2008.23.3.414","article-title":"Prognostic significance of HER2 gene amplification according to stage of breast cancer","volume":"23","author":"Kim","year":"2008","journal-title":"J Korean Med Sci"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0461-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0461-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222008110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222008110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-020-0461-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:41:30Z","timestamp":1760229690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222008110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0893395222008110"],"URL":"https:\/\/doi.org\/10.1038\/s41379-020-0461-z","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intense basolateral membrane staining indicates HER2 positivity in invasive micropapillary breast carcinoma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-020-0461-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}